Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant
The IAP antagonist Is In Phase III Trials For Head And Neck Cancer
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.
You may also be interested in...
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
The German group is optimistic evobrutinib can be a blockbuster in multiple sclerosis and has adapted its pivotal trial to cope with disruption caused by the war in Ukraine.
After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.